Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR1019
- Development stage
- Phase 3
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR1019 is an orally administered small molecule drug candidate being developed by Boryung Pharmaceutical for the treatment of hypertension and type 2 diabetes mellitus. It is classified as both an antihyperglycaemic and antihypertensive agent. The precise mechanism of action has not been defined in public sources. As of early 2025, it has reached phase III clinical trials for hypertension and type 2 diabetes mellitus in South Korea[1][2][3]. Clinical studies have also evaluated its pharmacokinetics and safety profile in healthy volunteers[7].
- Other names
- BR1019A-1BR-1019A-1BR 1019A-1BR1019 1BR-1019 1BR 1019 1BR1019ABR-1019ABR 1019A
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on BR1019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR1019.